[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreas-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreas-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,101,0,25,[9,43,74,111,154,183,206,235,265,288,321,352,375,396,426,453,472,493,543,563,588,612,644,670,691],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100639337","scheduled-meditation-for-improving-postoperative-outcomes-in-patients-undergoing-pancreatectomy-100639337",false,"NCT07608458","Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy","Scheduled Meditation for Perioperative Optimization: A Randomized Controlled Trial on Postoperative Outcomes, Pain, Anxiety, Insomnia, Stress, and Mobility in Pancreatectomy Patients","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n* Willing to install required apps on personal smartphone\n* Willing to wear a Garmin wearable device throughout the study\n* Age: ≥ 18 years\n* Ability to read and understand English for questionnaires\n* Owns a smartphone\n* Comfortable with routine smartphone use\n* Scheduled to undergo pancreatectomy\n\nExclusion Criteria:\n\n* Participants with prior formal training in meditation or mindfulness (e.g., completion of structured courses, workshops, or certification programs)\n* Participants who currently engage in a structured meditation or mindfulness practice, including regular use of mobile applications (e.g., Headspace, Calm, or similar platforms) or other formalized routines","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical trial tests the feasibility and how well a scheduled meditation intervention works to improve postoperative outcomes such as pain, anxiety, insomnia, stress and mobility for patients undergoing pancreatectomy. Many patients undergoing pancreatectomy surgery report clinically important fatigue, pain, and\u002For reduction in quality of life. Meditation is a behavioral intervention that has been studied in a variety of medical and surgical settings, where it has been associated with reductions in pain, anxiety, blood pressure, and lack of sleep, and in some cases with decreased pain and shorter length of stay. The meditation intervention using Headspace is an easily accessible and interactive way to complete scheduled meditation. This may improve postoperative outcomes for patients undergoing pancreatectomy.",[27,28,29],"Hepatocellular Carcinoma","Pancreas Cancer","Biliary Tract Neoplasms","NOT_YET_RECRUITING","2026-08-19",{"date":33,"type":34},"2026-08-20","ACTUAL",{"date":36,"type":21},"2026-10-01",{"date":38,"type":21},"2026-11-25",{"name":40,"class":41},"City of Hope Medical Center","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":4,"leadSponsor":71,"locationsCount":42},"100202701","obtaining-solid-tumor-tissue-from-people-having-biopsy-or-surgery-for-certain-types-of-cancer-100202701","NCT01915225","Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer","Tumor, Normal Tissue and Specimens From Patients Undergoing Evaluation or Surgical Resection of Solid Tumors","* INCLUSION CRITERIA:\n* Participants must be 2 years of age or older. Note: Participants greater than or equal to 2 and \\\u003C 18 years of age may only participate in research sample collection if the tissue acquisition is performed during a clinically indicated surgical procedure, and the biospecimen sampling (e.g., blood, urine, ascites, bile, or \\[clinically indicated\\] resected tumor tissue) does not add risk to the clinically indicated procedures.\n* Participants who have premalignant, primary, or metastatic solid tumors based upon either radiographic or clinical suspicion, biochemical testing, a genetic predisposition, or histological\u002Fcytological analysis that requires surgery or biopsy as part of the diagnosis, prevention, treatment, and\u002For follow-up.\n* Participants without solid tumors in whom a diagnostic, preventative, or therapeutic intervention is being performed, but for whom surgical quality and safety outcomes data are generated.\n* Participants should have laboratory and physical examination parameters within acceptable limits prior to biopsy or surgery.\n* Participants must be planning to undergo surgery or biopsy as part of their normal treatment plan.\n* Ability of participant, parent\u002Fguardian or legally authorized representative (LAR) to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nNone.","2 Years",{"count":52,"type":21},1800,"OBSERVATIONAL","Background:\n\n\\- Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to have a procedure at the National Institutes of Health Clinical Center (NIHCC).\n\nObjectives:\n\n\\- To collect tissue samples for use in studying new ways to treat tumors.\n\nEligibility:\n\n* Adults 18 years and older, with a precancerous or cancerous solid tumor who are scheduled to have surgery or a biopsy at the NIHCC.\n* Children under the age of 18 but who are older than 2 years of age are eligible to be enrolled on the research sample collection portion of this study if they will have a biopsy or surgery as part of their medical care.\n\nDesign:\n\n* Before their procedure, participants will have a small blood sample taken.\n* Some participants will undergo leukapheresis. In this procedure, blood is removed through a tube in one arm and circulated through a machine that removes white blood cells. The blood, minus the white blood cells, is returned through a tube in the other arm. The procedure takes 3-4 hours.\n* For all participants, during the surgery or biopsy, pieces of the tumor and pieces of normal tissue near it will be removed for this study. The rest of the tumor or precancerous growth will be sent to a lab for analysis.\n* Participants will return to the clinic about 6 weeks after the operation for a routine checkup. Some may have to return for additional follow-up.",[56,57,58,59,28],"Colorectal Neoplasms","Gastric Neoplasms","Cholangiocarcinoma","Bile Duct Cancer",[61,62,63,64],"Tissue Procurement","Surgery","Metastasectomy","Natural History","RECRUITING","2026-08-15",{"date":68,"type":34},"2026-08-18",{"date":70,"type":34},"2013-07-21",{"name":72,"class":73},"National Cancer Institute (NCI)","NIH",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":96,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":42},"100514215","microenvironment-tumor-effects-of-radiotherapy---comprehensive-radiobiology-assessment-trial-100514215","NCT05975593","MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial","MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial (METEOR-CRATR)","METEOR-CRATR","Inclusion Criteria:\n\n* Confirmation of intent to receive radiotherapy for one of the following diagnoses:\n\n  * Cervical cancer\n  * Pancreatic cancer\n* ECOG performance status ≤ 2\n* At least 18 years old\n* Able to understand and willing to sign an IRB-approved written informed consent document\n\nExclusion Criteria:\n\n* Any issue (medical, anatomic, other) that might preclude safe acquisition of biospecimens at the discretion of the treating physician",{"count":83,"type":21},60,[24],"This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally advanced cervical and pancreatic cancer.",[87,88,89,90,91,92,28,93,94,95],"Locally Advanced Cervical Carcinoma","Locally Advanced Cervical Cancer","Locally Advanced Pancreas Cancer","Locally Advanced Pancreatic Carcinoma","Locally Advanced Pancreatic Cancer","Cervical Cancer","Pancreatic Cancer","Cancer of the Cervix","Cancer of the Pancreas",[97,98,99,100,101],"Radiotherapy","Chemotherapy","Cervical cancer","Pancreatic cancer","Biospecimen","2026-08-12",{"date":104,"type":34},"2026-08-17",{"date":106,"type":34},"2024-01-11",{"date":108,"type":21},"2032-12-31",{"name":110,"class":41},"Washington University School of Medicine",{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":153},"100534718","phase-1-a-study-of-mgc026-in-participants-with-advanced-solid-tumors-100534718","NCT06242470","A Study of MGC026 in Participants With Advanced Solid Tumors","A Phase 1\u002F1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Adults ≥ 18 years old, able to provide informed consent\n* Adequate performance and laboratory parameters\n* Availability of archival or formalin-fixed paraffin-embedded tumor tissue sample. Participants may undergo a fresh tumor biopsy to obtain a specimen for testing if an archival tumor sample is not available. Participants with no available archival tissue sample who cannot safely undergo a fresh biopsy as determined by consultation between the sponsor and investigator are eligible\n* Unresectable, locally advanced or metastatic solid tumors including: squamous cell cancer (SCC) of the head and neck, esophageal SCC, squamous and non-squamous non-small cell lung cancer, small cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, castration resistant prostate cancer, breast cancer, ovarian cancer, cervical cancer, colorectal cancer gastric or gastroesophageal cancer, pancreatic carcinoma, clear cell renal cell cancer or hepatocellular cancer.\n* Measurable disease per RECIST v1.1. Participants with metastatic CRPC without measurable disease are eligible.\n* Must be willing to use highly effective methods of birth control from the time of consent through 7 months after discontinuation of MGC026.\n* Not pregnant or breastfeeding.\n\nExclusion Criteria:\n\n* Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.\n* Another cancer that required treatment within the past 2 years, with the exception of those with low risk of cancer spreading or death such as adequately treated non melanomatous skin cancer, localized prostate cancer (Gleason Score \\\u003C 6), or carcinoma in situ.\n* Patients with history of prior central nervous system (CNS) metastasis must have been treated, be asymptomatic, and not have concurrent treatment for CNS disease, progression of CNS metastases on magnetic resonance imaging, computed tomography or positron emission tomography, or history of leptomeningeal disease or cord compression at the time of enrollment.\n* Treatment with surgery, systemic cancer therapy, immunotherapy, chimeric antigen receptor-T therapy, or anti-hormonal within protocol specified intervals.\n* Prior treatment with any B7-H3 targeted agent for cancer or any ADC with a topoisomerase payload.\n* Prior autologous or allogeneic stem cell or solid organ transplant.\n* Clinically significant cardiovascular, pulmonary, or gastrointestinal disorders.\n* Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 1 week of first study drug administration.\n* Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction.\n* Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.\n* History of primary immunodeficiency.\n* Major trauma or major surgery within 4 weeks of first study drug administration.\n* Known hypersensitivity to recombinant proteins.",{"count":119,"type":21},250,[121],"PHASE1","The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study.\n\nParticipants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.",[124,125,126,127,128,129,130,131,132,133,134,92,135,136,137,28,138,27,139,140,141,142],"Advanced Solid Tumor","Advanced Cancer","Metastatic Cancer","Squamous Cell Carcinoma of Head and Neck","Non Small Cell Lung Cancer","Small-cell Lung Cancer","Bladder Cancer","Sarcoma","Endometrial Cancer","Melanoma","Castration Resistant Prostatic Cancer","Colorectal Cancer","Gastric Cancer","Gastro-esophageal Cancer","Clear Cell Renal Cell Carcinoma","Platinum-resistant Ovarian Cancer","Breast Cancer","Ovarian Cancer","Esophageal Squamous Cell Cancer (SCC)","2026-08-10",{"date":145,"type":34},"2026-08-11",{"date":147,"type":34},"2024-03-06",{"date":149,"type":21},"2028-10",{"name":151,"class":152},"MacroGenics","INDUSTRY",12,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":17,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":171,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":42},"100641453","transcriptional-pathways-of-surgical-pain-modulated-by-music-therapy-exposure-transpose-100641453","NCT07653594","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE): A Single Arm Pilot Study","Inclusion Criteria:\n\n* Age 50 to 80\n* Able to speak and understand English\n* Scheduled to undergo a surgery meeting the following criteria: (1) traditional open surgery (not laparoscopic or robotic) via laparotomy (midline or subcostal incisions), (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces\n* Participant reports pain intensity of 4\u002F10 or above to study staff on day 1 post-surgery or any other day post-surgery through discharge\n\nExclusion Criteria:\n\n* Significant visual impairment that has not been corrected\n* Significant hearing impairment that has not been corrected\n* Significant cognitive impairment that would prevent participant from participating in the study","50 Years","80 Years",{"count":164,"type":21},20,[24],"Participants may take part in this study if they are scheduled to undergo a surgery that meets the following: (1) traditional open surgery via laparotomy, (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces. The purpose of this study is (1) to evaluate the feasibility of collecting blood samples prior to surgery, post-surgery and pre- music-assisted relaxation and imagery (MARI) intervention, and immediately post-MARI intervention and (2) to identify gene expression changes associated with MARI and explore their relationship with immediate changes in pain intensity. Participants will be in this study for the duration of their hospital admission for surgery.",[62,168,28,59,169,170],"Stomach Cancer","Liver Cancer","Peritoneal Cancer",[172,173],"Music therapy","Music-assisted relaxation and imagery","2026-08-03",{"date":176,"type":34},"2026-08-05",{"date":178,"type":21},"2027-01",{"date":180,"type":21},"2027-12",{"name":182,"class":41},"Case Comprehensive Cancer Center",{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100561689","phase-3-extending-outcomes-for-pancreas-cancer-patients-with-nominal-oligometastatic-disease-expand-a-randomized-phase-iii-trial-100561689","NCT06593431","Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial","Inclusion Criteria:\n\nAge 18\n\nHistologically or cytologically confirmed pancreatic ductal adenocarcinoma.\n\nHistologic \u002F cytologic confirmation of pancreatic ductal adenocarcinoma may come from the primary tumor (i.e., via FNA at initial diagnosis). Histological\u002Fpathologic confirmation of distant metastatic disease is not required if clinical and radiographic consensus is that the patient has distant metastatic disease.\n\nEastern Cooperative Oncology Group (ECOG) performance status ≤2\n\nCandidate for MDT (including radiation therapy, surgical resection, ablation, and embolization) to all sites of disease including oligometastatic sites and if present intact primary \u002F regional nodal disease.\n\nBetween one and five distant metastatic lesions, counted as follows: each lesion (not site) will be counted as one, with the exception of metastatic lymph node stations, which will collectively count as one lesion. Regional nodal stations will be counted as a collective single lesion if present. All progressive lesions must be amenable to local therapy as noted in criterion 4.2.1.4 above.\n\nCounting of oligometastatic nodal disease will be based on nodal chains. A nodal chain will be considered a single metastatic lesion if the presence of that node results in the patient as having M1 disease per the TNM staging system, AJCC version 8.0. In addition, one of the following criteria must be met: a) ≥1 LN meets radiologic criteria for metastatic disease via RECIST 1.1 (short axis ≥15mm), b) pathologic assessment has confirmed the presence of metastatic cancer cells, and\u002For c) the LN exhibits imaging signal characteristic of a metastatic lesion (e.g. FDG avidity, contrast enhancement, etc.). In the event of ambiguity or equivocal findings, the principal investigator or co-principal investigator will make a final determination of whether criteria are met. The following caveats apply:\n\nIn patients with a LN exhibiting a short axis ≥15mm and who have other diagnoses that can produce enlarged LNs (e.g. indolent CLL, sarcoidosis, etc…) or a prior history of benign enlarged LNs will not be considered to have metastatic disease per the discretion of the treating physician.\n\nLN chains that occur bilaterally will be considered separate metastatic sites. For example, left axilla LNs will counted separately from right axilla LNs.\n\nThe following midline LN chains will be counted as 1 metastatic site: mediastinal, para-aortic, mesenteric.\n\nThe following bilateral LN chains will be counted as 1 metastatic site for unilateral involvement, and 2 for bilateral for involvement: preauricular, cervical and occipital, supraclavicular, infraclavicular, pectoral, axillary, hilar, epitrochlear and brachial, iliac, inguinal and femoral, popliteal.\n\nBaseline imaging must include a scan done within 4 weeks prior to randomization, demonstrating oligometastatic disease by RECIST (v1.1) criteria compared to pre-baseline imaging.\n\nBaseline imaging must be done within 4 weeks prior to randomization, and the following imaging is required: PET\u002FCT scan or CT scan of the chest\u002Fabdomen\u002Fpelvis. MRI may be substituted as indicated (i.e., CT scan of chest plus MRI abdomen\u002Fpelvis).\n\nDiagnostic laparoscopy may be indicated prior to enrollment if any concern for peritoneal disease \u002F carcinomatosis is present, at the investigator's discretion. Presence of peritoneal carcinomatosis will exclude the patient from this trial as below. Indications for peritoneal carcinomatosis may include findings concerning for but not definitive for peritoneal disease on diagnostic imaging, elevated CA-19-9, and clinical symptoms concerning for peritoneal disease.\n\nPatients referred for the study that require immediate MDT can receive treatment to CNS lesions or other symptomatic lesions prior to randomization, but these lesions will be counted towards the total number of oligometastatic lesions.\n\nPatients with \\>5 discrete metastatic sites previously with subsequent 'induction' of oligometastatic disease (\\<=5 discrete sites; induction via response to systemic therapy) may be eligible if 5 or fewer metastatic disease sites have been present \u002F noted radiographically for a minimum of 6 months, and pending principal investigator review\u002Fdiscretion.\n\nFemales of childbearing potential must not be breast feeding and must have a negative serum or urine pregnancy test and must agree to use adequate contraception from the time of screening until 3 months after discontinuation of the study medication. Acceptable methods of contraception include total and true sexual abstinence, tubal ligation, hormonal contraceptives that are not prone to drug-drug interactions (IUS Levonorgestrel Intra Uterine System (Mirena), Medroxyprogesterone injections (Depo-Provera), copper-banded intra-uterine devices, and vasectomized partner. All hormonal methods of contraception should be used in combination with the use of a condom by their sexual male partner. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause). Women will be considered post-menopausal if they have been amenorrheic for the past 12 months without an alternative medical cause. The following age-specific requirements must also apply: Women \\< 50 years old: they would be considered post-menopausal if they have been amenorrheic for the past 12 months or more following cessation of exogenous hormonal treatments. The levels of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) must also be in the post-menopausal range (as per the institution). Women ≥ 50 years old: they would be consider post-menopausal if they have been amenorrheic for the past 12 months or more following cessation of all exogenous hormonal treatments, or have had radiation-induced oophorectomy with the last menses \\> 1 year ago, or have had chemotherapy-induced menopause with \\>1 year interval since last menses, or have had surgical sterilization by either bilateral oophorectomy or hysterectomy.\n\nNon-sterilized males who are sexually active with a female partner of childbearing potential must use adequate contraception for the duration of the study and 6 months after the last dose of study medication. Adequate contraception methods include: birth control pills (e.g. combined oral contraceptive pill), barrier protection (e.g. condom plus spermicide, cervical\u002Fvault cap or intrauterine device), and abstinence. Patients should not father a child for 6 months after completion of the study medication. Patients should refrain from donating sperm from the start of dosing until 6 months after discontinuing the study medication. If male patients wish to father children they should be advised to arrange for freezing of sperm samples prior to the start of the study medication.\n\nDemonstration of adequate organ function as defined in the table below, all screening labs to be performed within 4 weeks prior to study enrollment:\n\nExclusion Criteria\n\nMetastatic effusion (e.g. pleural effusion or ascites). Note that patients with an effusion that is too small to sample will be eligible for the trial.\n\nLeptomeningeal disease.\n\nPeritoneal carcinomatosis.\n\nCognitively impaired subjects (e.g. inability to sign informed consent.)\n\nAny condition that, in the opinion of the investigator, would interfere with the study treatment or interpretation of the study results.\n\nDiffuse bone marrow involvement as defined by disease involvement of a BM biopsy from a site that does not have radiologic evidence of a bone metastasis.\n\nMore than 4 prior lines of systemic therapy to treat metastatic disease.\n\nDiagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe delivery of radiotherapy. Such patients may be eligible if dispositioned to non-radiotherapy MDT.\n\nKnown psychiatric or substance abuse disorder\u002Fs that would interfere with trial participation.\n\nConcurrent (synchronous or metachronous) other primary malignancy that in the opinion of the treating physician team presents a substantial risk to the patient's life as a competing risk of death (against the primary oligometastatic pancreatic cancer being considered for MDT as part of this trial).",{"count":190,"type":21},80,[192],"PHASE3","The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).",[28,195],"Oligometastatic","2026-07-24",{"date":198,"type":34},"2026-07-27",{"date":200,"type":34},"2024-10-23",{"date":202,"type":21},"2029-06-29",{"name":204,"class":41},"M.D. Anderson Cancer Center",4,{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":213,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":216,"conditions":217,"keywords":222,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":42},"100649344","analysis-of-breath-volatile-organic-compounds-using-mass-spectrometry-100649344","NCT07732686","Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry","Breath Volatile Organic Compounds (VOC) Analysis Using Proton Transfer Reaction Mass Spectrometry (PTR-MS)","Inclusion Criteria:\n\n* Age ≥ 18 at the time of consent. Male and female patients to be tested.\n* Capable of understanding written and\u002For spoken English language.\n* Able to provide informed consent.\n* Cancer of any type.\n* Newly diagnosed cancer and untreated or established diagnosis of cancer. For established cancer patients, no active anti-cancer treatment for more than one month (reasons for no treatment are such as relapse, progression of cancer, refractory, or intolerance to treatment etc.)\n\nExclusion Criteria:\n\n* Under the age of 18.\n* Anticipated inability to complete breath sampling procedure.\n* Unable to provide informed consent.\n* Pregnant women\n* Active respiratory infection symptoms\n* Recent use of antibiotics\n* Difficulty in performing coached exhalation\n* Individuals who are unable to follow the instructions\n* Cancer patients who are on active treatment for cancer or have received cancer treatment within one month",true,{"count":215,"type":21},2000,"The purpose of this clinical trial is to evaluate whether volatile organic compound (VOC) signatures detected in the breath of patients with cancer can serve as a potential screening tool for the early detection of cancer.",[28,27,218,141,140,219,220,130,221],"Lung Cancer","Head and Neck Cancer","Colon Cancer","Other Cancer",[223,224,225],"VOC","PTR-MS","ML","2026-07-23",{"date":228,"type":34},"2026-07-29",{"date":230,"type":21},"2026-10",{"date":232,"type":21},"2029-10",{"name":234,"class":41},"University of Oklahoma",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":250,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":264},"100558040","phase-1-study-of-orally-administered-moma-313-in-participants-with-advanced-or-metastatic-solid-tumors-100558040","NCT06545942","Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors","A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Have histologically confirmed disease for each treatment arm as follows:\n\n   1. Treatment Arm 1 (MOMA-313 Monotherapy)\n\n      \\- Advanced (including locally), relapsed or metastatic solid tumors that are not eligible for curative therapy, with any HR-deficient alteration.\n   2. Treatment Arm 2 (MOMA-313 in Combination with Olaparib):\n\n      * Dose escalation: Advanced (including locally), relapsed or metastatic solid tumors that are not eligible for curative therapy, for which a PARP inhibitor is indicated, with select HR-deficient mutations. Patients may be PARP inhibitor naive or exposed.\n      * Dose optimization: Advanced (including locally), relapsed or metastatic CRPC or pancreatic ductal adenocarcinoma (PDAC) with select HR-deficient mutations. Patients must be PARP inhibitor naive.\n3. Have at least 1 lesion at baseline (measurable or non-measurable) suitable for repeat imaging evaluation by RECIST and\u002For PCWG-3\n4. ECOG PS ≤ 2\n5. Fully recovered from clinically relevant effects of prior therapy, radiotherapy, and\u002For surgery \\*\\*hormonal therapy allowed. Palliative radiotherapy allowed.\n6. Adequate organ function per local labs\n7. Comply with contraception requirements\n8. Written informed consent must be obtained according to local guidelines\n\nKey Exclusion Criteria:\n\n1. Active prior or concurrent malignancy (some exceptions allowed)\n2. Clinically relevant cardiovascular disease\n3. Known CNS metastasis associated with progressive neurological symptoms (stable doses of corticosteroids allowed)\n4. Known active infection\n5. Prior polymerase theta inhibitor exposure\n6. Known allergy, hypersensitivity, and\u002For intolerance to MOMA-313\n7. Olaparib exposed patients with known hypersensitivity to PARP inhibitors (for patients considered for olaparib only)\n8. Impaired GI function that may impact absorption.\n9. Patient is pregnant or breastfeeding.\n10. Known to be HIV positive, unless all of the following criteria are met:\n\n    1. Undetectable viral load or CD4+ count ≥300 cells\u002FμL\n    2. Receiving highly active antiretroviral therapy\n    3. No AIDS-related illness within the past 12 months\n11. Active liver disease (some exceptions are allowed)\n12. Prior or ongoing condition, therapy, or laboratory abnormality that, in the investigator's opinion, may affect safety of the patient, confound the results of the study, and\u002For interfere with the patients participation in the study",{"count":243,"type":21},220,[121],"This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.",[124,247,248,28,140,141,249],"Metastatic Solid Tumor","Prostate Cancer","Homologous Recombination Deficiency",[251,252,253,254,124,247,248,28,140,141,249,255,256],"Phase 1","MOMA-313","Polymerase theta","MOMA Therapeutics","HRD Mutation","Advanced (including locally)","2026-07-22",{"date":226,"type":34},{"date":260,"type":34},"2024-08-13",{"date":262,"type":21},"2027-11-30",{"name":254,"class":152},18,{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":213,"sex":17,"minAge":18,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":83},"100436960","pancreatic-cancer-early-detection-consortium-100436960","NCT04970056","Pancreatic Cancer Early Detection Consortium","PRECEDE","Inclusion Criteria:\n\nIndividuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database:\n\nCohort 1\n\nIndividuals without history of PDAC meeting any of the following criteria:\n\n1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.\n2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family\n3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family\n4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+\n5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+\n6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+\n\nCohort 2\n\nIndividuals without history of PDAC meeting any of the following criteria:\n\n1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+\n2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family\n3. 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member\n\nCohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)\n\nCohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.\n\nCohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and\u002For buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.\n\nCohort 6a\n\nIndividuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:\n\n1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other\n2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11\n\nCohort 6b\n\nIndividuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:\n\n1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other\n2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11\n3. Diagnosed ≤ age 45\n\nCohort 6c Individuals with newly diagnosed early stage (stage I or stage II) PDAC seen at a PRECEDE site that do not meet the criteria for 6a or 6b.\n\nCohort 6d Individuals with PDAC seen at a PRECEDE site that do not meet the criteria for 6a, 6b, or 6c.\n\nCyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)\n\nExclusion Criteria:\n\n* Individuals not meeting the criteria above.","90 Years",{"count":274,"type":21},20000,"The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and\u002For individuals carrying pathogenic\u002Flikely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.",[28,277,278,279],"Pancreas Cyst","Pancreatic Ductal Adenocarcinoma","Genetic Predisposition","2026-07-21",{"date":257,"type":34},{"date":283,"type":34},"2020-09-18",{"date":285,"type":21},"2030-12-31",{"name":287,"class":41},"Arbor Research Collaborative for Health",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":299,"conditions":300,"keywords":309,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":42},"100645726","a-liquid-biopsy-for-pancreatic-cancer-early-detection-and-disease-monitoring-100645726","NCT07700992","A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring","An Exosome-based and Machine-learning-powered Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring","PANXEON","Inclusion Criteria:\n\n* Adult men or women aged ≥18 years at the time of plasma sample collection.\n* Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to familial pancreatic cancer or hereditary pancreatic cancer syndrome\n* Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to the presence of one (or more) mucinous pancreatic cystic lesion(s).\n* Availability of stored plasma samples collected as part of routine clinical care or surveillance and archived in the institutional biobank.\n* Availability of relevant clinical and demographic data in institutional medical records sufficient to address study objectives.\n* Prior provision of informed consent for biobanking and research use of biological samples and data\n\nExclusion Criteria:\n\n* Absence or insufficient quality\u002Fquantity of stored plasma samples for laboratory analysis.\n* Lack of clinical data required for cohort classification and\u002For outcome assessment.\n* History of pancreatic surgery or interventional procedures prior to plasma sample collection.\n* Concurrent active malignancy at the time of sample collection, other than non-melanoma skin cancer.\n* Samples collected outside routine clinical care or not compliant with institutional biobanking and data protection policies.","99 Years",{"count":298,"type":21},600,"Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these approaches are invasive, costly, and suboptimal in sensitivity. The aim of this study is to evaluate circulating cell-free and exosome-bound microRNAs as non-invasive biomarkers of PDAC risk and disease biology",[301,302,303,304,28,305,306,277,307,308],"Familial Pancreatic Cancer","Familial Pancreatic Carcinoma","Hereditary Pancreatic Cancer","Hereditary Pancreatitis","Pancreas Neoplasm","Pancreas Adenocarcinoma","Pancreatic Neoplasms","Intraductal Papillary Mucinous Neoplasm",[310,311],"Early detection","Liquid biopsy","2026-07-13",{"date":314,"type":34},"2026-07-14",{"date":316,"type":34},"2026-06-03",{"date":318,"type":21},"2032-01-30",{"name":320,"class":41},"Università Vita-Salute San Raffaele",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":350,"locationsCount":42},"100560657","phase-2-repurposing-riluzole-for-cancer-related-cognitive-impairment-a-pilot-trial-100560657","NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial","Inclusion Criteria:\n\n1. Cohort-specific inclusion for male and female patients.\n\n   a. Cohort A (no prior cranial radiation) i. Diagnosed with one of the following:\n   * Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and\u002For other breast cancer interventions.\n   * Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years.\n   * Non-breast cancer patients exposed to other anticancer therapies within the past 3 years.\n\n     b. Cohort B (prior cranial radiation)\n   * Previously received radiotherapy or radiosurgery to the brain for benign, malignant, or metastatic tumors.\n   * Life expectancy \\> 6 months\n2. Washout from investigational and conventional interventions is up to the discretion of the investigator. Concurrent participation in another intervention is allowable if judged by the Principal Investigator that this would not be scientifically or medically incompatible with this study.\n3. ≥18 years of age\n4. Perceived by patient or investigator that cognitive function has worsened since receipt of cranial radiation or cancer treatment.\n5. Able to provide informed consent.\n6. Literacy in English, Chinese, Korean, Vietnamese, or Spanish, to complete the questionnaires.\n7. Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes.\n\n   * Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.\n\nExclusion Criteria:\n\n1. Cohort-specific exclusion for male and female patients:\n\n   1. Cohort A (no prior cranial radiation)\n\n      * History of or current presence of primary brain tumors or brain metastases.\n   2. Cohort B (prior cranial radiation)\n\n      * Diagnosed with high grade glioma.\n2. Unwilling to undergo neuropsychological assessments necessary for the study.\n3. Women who are breastfeeding, pregnant or are planning to get pregnant during the study period. Persons of child-bearing potential (POCBP) must have a negative pregnancy test at screening if there is suspicion of pregnancy.\n\n   a. Female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n4. History of suspected hypersensitivity to riluzole or to any of its excipients.\n5. Patients taking or planned to take medications\u002Fsubstances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.\n6. Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN)\n7. Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.",{"count":329,"type":21},75,[331],"PHASE2","This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.",[140,131,136,218,219,135,141,169,334,335,336,337,338,339,248,28,340,341,342,133,343,344],"Genitourinary Cancer","Gynecologic Cancer","Urinary Bladder Cancer","Leukemia","Lymphoid Leukemia","Myeloma Multiple","Non-hodgkin Lymphoma","Hodgkin Lymphoma","Brain Cancer","Mycosis Fungoides","Kidney Cancer","2026-07-11",{"date":314,"type":34},{"date":348,"type":34},"2024-12-02",{"date":180,"type":21},{"name":351,"class":41},"University of California, Irvine",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":361,"conditions":362,"keywords":363,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":374},"100638938","a-study-of-magnetic-resonance-imaging-of-the-pancreas-for-cancer-screening-100638938","NCT07612046","A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening","Pilot Study of a Dedicated MR of the Pancreas: Improving Screening for Patients at High Risk for Pancreas Cancer","Inclusion Criteria:\n\n* Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual\n* Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first\u002Fsecond-degree relative with pancreas cancer\n* Pathogenic mutation in CDKN2A\u002Fp16, STK11, PRSS1, SPINK1\u002FPST1, CTRC, CPA1, ATM, or BRCA2\n* Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+\n\nFor this pilot MRP study, we will additionally apply the following Criteria:\n\n* Consents to follow-up contact\n* US residents\n* Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)\n* No metallic artifacts covering the pancreas on prior MRCP\n* Scheduled for endoscopic ultrasound\n* No new contraindications for MRI (e.g. new MR unsafe device)\n* No history of claustrophobia or use of anxiolytic on prior MRI\n* No history of abdominal surgery that may affect interpretation of either EUS or MR\n* No medical conditions that confers increased and\u002For unacceptable risk for anesthesia\n\nWe will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in \\~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget.\n\n* Documentation of Disease\n\n  o No pathologic confirmation of disease is necessary\n* Definition of Disease N\u002FA\n* Required Organ Function N\u002FA\n\nExclusion Criteria:\n\n\\-",{"count":360,"type":21},79,"The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.",[93,28],[93,28,364,365],"Memorial Sloan Kettering Cancer Center","26-174","2026-07-08",{"date":368,"type":34},"2026-07-09",{"date":370,"type":34},"2026-05-20",{"date":372,"type":21},"2028-05-20",{"name":364,"class":41},7,{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":42},"100537821","the-histosonics-edison-system-for-treatment-of-pancreatic-adenocarcinoma-using-histotripsy-100537821","NCT06282809","The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy","GANNON","Inclusion Criteria:\n\n1. Subject is ≥18 years of age.\n2. Subject has signed the Ethics Committee (EC) approved trial Informed Consent Form (ICF) prior to any trial related tests\u002Fprocedures and is willing to comply with trial procedures and required follow-up assessments.\n3. Subject is diagnosed with unresectable pancreatic adenocarcinoma (locally advanced \\[Stage 3\\] or oligometastatic disease \\[Stage 4\\]) confirmed via CT or MR imaging ≤14 days prior to the planned index procedure.\n\n   NOTE: If Stage 4 disease, there must be ≤5 metastatic tumors, the tumors must be located only in the liver and\u002For lung, and the metastatic tumors must be stable.\n4. Subject is not a surgical candidate and has received chemotherapy ≥8 weeks.\n5. Subject can tolerate general anesthesia.\n6. Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-1 at baseline.\n7. Subject meets the following criteria ≤14 days prior to the planned index procedure date:\n\n   * Hemoglobin ≥ 9 g\u002FdL,\n   * Neutrophil count \\>1.0 x 10\\^9\u002FL,\n   * Platelet \\>50 x 10\\^9\u002FL,\n   * Total bilirubin ≤2.5x Institutional Upper Limit of Normal (IULN),\n   * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5x IULN,\n   * International Normalized Ratio (INR) value \\\u003C1.5,\n   * Serum creatinine \\\u003C2.0mg\u002FdL or an estimated glomerular filtration rate (eGFR) ≥45mL\u002Fmin.\n8. The targeted pancreatic tumor is ≥2 cm in longest diameter.\n9. The planned histotripsy treatment volume is ≥1.0 cm from any portion of the duodenum, small intestine, stomach, or colon as visualized on ultrasound, and CT, or MR imaging.\n10. Subject has an adequate acoustic window to visualize targeted tumor using the HistoSonics Edison System.\n11. Subject will undergo histotripsy treatment of only one (1) tumor during the index procedure, regardless of how many tumors are present in the pancreas.\n\nExclusion Criteria:\n\n1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the trial period.\n2. Subject has had prior pancreatic, bilioenteric, or gastric surgery.\n3. Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial.\n4. Subject has an uncorrectable coagulopathy.\n5. Subject has a life expectancy of less than six (6) months.\n6. Subject has a biliary or pancreatic stent and\u002For percutaneous biliary tube that encompasses the planned histotripsy treatment volume.\n7. Subject has metastases to organs other than the liver and\u002For lung (e.g., bone, brain, peritoneum).\n8. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.\n9. Subject has an active duodenal or gastric ulcer requiring medical management.\n10. Subject is undergoing active chemotherapy for any cancer ≤7 days prior to planned index procedure date.\\*\n11. Subject is undergoing active immunotherapy or targeted therapies ≤30 days prior to planned index procedure date.\n12. Subject's targeted tumor has had prior locoregional therapy (e.g., ablation, embolization, or radiation).\n13. Subject has a planned cancer treatment (e.g., pancreatic surgery, targeted therapy, immunotherapy) exclusive of chemotherapy, ≤30 days post index procedure.\n14. Subject has planned chemotherapy ≤14 days post index procedure.\\*\n15. Subject has not recovered (CTCAE grade 2 or better) from chemotherapy or immunotherapy related toxicities (exclusive of alopecia, neuropathy, and exocrine insufficiency).\n16. In the investigator's opinion, histotripsy is not a treatment option for the subject.\n17. Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.\n18. Subject's tumor is not treatable by the System's working ranges (refer to User Guide).\n\n(\\*) Subject must not be off chemotherapy \\>21 days in total.",{"count":383,"type":21},50,[24],"The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy.",[28,387,93,388],"Adenocarcinoma of the Pancreas","Tumor of Pancreas",{"date":368,"type":34},{"date":391,"type":34},"2024-12-10",{"date":393,"type":21},"2028-08",{"name":395,"class":152},"HistoSonics, Inc.",{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":22,"phases":405,"briefSummary":406,"conditions":407,"keywords":411,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":425},"100644592","integrating-systematic-patient-reported-evaluations-in-multi-disciplinary-tumor-boards-the-inspire-study-100644592","NCT07671937","INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study","INSPIRE","Inclusion\u002FExclusion Criteria: We will include two populations: (1) patients and (2) clinical team members involved in the MDTB.\n\nInclusion Criteria:\n\n* Inclusions Criteria- Patients:\n\n  1. aged 18 years or older;\n  2. with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis;\n  3. intention to be treated at a participating institution;\n  4. with verbal fluency in English or Spanish; and\n  5. scheduled to be discussed at MDTB.\n* Inclusion criteria - Clinicians:\n\nAll clinical team members participating in the pancreatic, breast, or gynecologic MDTB at a participating site will be included and have pre-emptively agreed to participation.\n\nExclusion Criteria:\n\n* Exclusion criteria - Patients:\n\nIndividuals with plans to receive cancer treatment outside the participating institution and inability to speak English or Spanish.\n\n* Exclusion criteria - Clinician:\n\nClinicians will retain the opportunity to opt-out of participation, in which case their portions of the discussion will not be included in the analysis; however, this is not anticipated based on pilot data.",{"count":404,"type":21},2748,[24],"The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves including electronic patient reported outcomes (ePROs) within MDTB on MDTB discussion content, provider burden, treatment recommended and received, healthcare utilization, and patient-reported outcomes.",[140,408,409,28,410],"Corpus Uteri Cancer","Ovary Cancer","Other Female Genital Malignant Neoplasms",[412,413,414,93,140,415],"PROs","Multidiscipinary tumor board","INSPIRE intervention","gynecologic cancers","2026-06-30",{"date":418,"type":34},"2026-07-02",{"date":420,"type":21},"2026-09-01",{"date":422,"type":21},"2031-07",{"name":424,"class":41},"University of Alabama at Birmingham",3,{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":434,"enrollmentInfo":435,"targetDuration":4,"studyType":22,"phases":437,"briefSummary":438,"conditions":439,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":42},"100594635","predictive-risk-factors-for-pancreatic-fistula-after-pancreaticoduodenectomy-100594635","NCT07022015","Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy","Predictive Risk Factors for Postoperative Pancreatic Fistula After Pancreaticoduodenectomy for Malignancy.","POPF","Inclusion Criteria:\n\n* Patients with resectable distal common bile duct carcinoma, periampullary carcinoma, duodenal carcinoma, and carcinoma of the head of the pancreas.\n* Patients meeting the curative treatment intent in accordance with clinical guidelines:\n\n  * No evidence of metastasis.\n  * Radiological non-involvement of superior mesenteric vein \\& portal vein.\n* American Society of Anesthesiologists (ASA) scores I \\& II.\n* Patients aged \\> 18 years.\n* Ability to understand and the willingness to sign a written informed consent document\n* Agreement to complete the study\n\nExclusion Criteria:\n\n* Unfit patients for surgery due to severe medical illness.\n* Inoperable patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs.\n* Irresectable tumors in diagnostic laparoscopy.\n* History of other malignant disease.\n* Pregnant or breast-feeding women.\n* Patients with serious mental disorders.\n* Patients with vascular invasion and requiring vascular resection as evaluated by the multidisciplinary team according to abdominal imaging data.\n* Pancreatoduodenectomy for other diagnosis like cystic lesions, benign tumors or chronic calcific pancreatitis\n* Patients refused to participate in the study.","75 Years",{"count":436,"type":21},100,[24],"Pancreaticoduodenectomy (PD) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality. Postoperative pancreatic fistula (POPF) is the most common and clinically significant complication following PD. In this study, the investigators aim to determine the predictive risk factors for clinically related postoperative pancreatic fistula (CR-POPF) in the preoperative, intraoperative and postoperative period in patients that underwent PD. The total number of 100 participants expected to be included in this research who underwent PD between 2025 and 2026.",[28,305,440,306,441,442,443],"Pancreatic Fistula","Periampullary Cancer","Periampullary Carcinoma","Resectable Pancreatic Cancer","2026-06-27",{"date":446,"type":34},"2026-07-01",{"date":448,"type":34},"2025-06-20",{"date":450,"type":21},"2026-10-20",{"name":452,"class":41},"Minia University",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":425},"100409795","evaluating-the-prognostic-capability-of-ctdna-as-a-biomarker-in-pancreatic-cancer-patients-undergoing-neoadjuvant-chemotherapy-100409795","NCT04616131","Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy","Inclusion Criteria:\n\n* Biopsy or cytology proven adenocarcinoma of the pancreas\n* No clinical evidence of metastatic disease on imaging\n* Age 18 or older\n* Receiving chemotherapy for non-metastatic pancreatic cancer\n\nExclusion Criteria:\n\n* Biopsy proven metastatic disease",{"count":460,"type":21},500,"For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.",[28],"2026-06-16",{"date":465,"type":34},"2026-06-18",{"date":467,"type":34},"2020-10-01",{"date":469,"type":21},"2029-10-01",{"name":471,"class":41},"Northwestern University",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":42},"100552911","phase-1-study-of-egfrbi-armed-fresh-pbmc-in-metastatic-or-unresectable-pancreatic-cancer-100552911","NCT06479239","Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer","Phase I\u002FII Study of Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells (EGFR FPBMC) in Metastatic or Unresectable Pancreatic Cancer","Panc 002","Inclusion Criteria:\n\n1. Histologically confirmed locally advanced pancreatic cancer (LAPC)\u002Funresectable pancreatic cancer (UPC) or metastatic pancreatic cancer (MPC) not eligible for curative intent therapy\n2. Received at least 1 line of chemotherapy and have stable disease (SD) or better for 3 months prior to enrollment. Therapy should consist of either a gemcitabine, 5FU-based (including capecitabine) or albumin-bound paclitaxel-based regimen. Patients with actionable mutations should have received targeted therapy prior to enrollment on trial. Patients who qualify for immunotherapy due to mismatch repair protein\u002Fmicrosatellite stable and tumor mutational burden status should also have received immunotherapy prior to enrollment on trial.\n3. Measurable disease by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n5. Age ≥ 18 years\n6. Females of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment\u002Fregistration\n7. Females of childbearing potential and males must agree to use an effective method for contraception for the duration of the treatment with study drug plus 90 days (duration of sperm turnover). Males must also abstain from sperm donations during study treatment and for at least 90 days after the last dose of study drug.\n8. Adequate organ function within 14 days prior to registration, defined as the following:\n\n   * Absolute neutrophil count \\>= 500\u002Fmm3\n   * Absolute lymphocyte count \\>= 400\u002Fmm3\n   * Platelets \\>= 75,000\u002Fmm3\n   * Hemoglobin \\>= 8 g\u002FdL\n   * Serum creatinine \\\u003C 2.0mg\u002FdL or calculated\u002Fmeasured creatinine clearance \\>= 50 ml\u002Fmin\n   * Bilirubin \\\u003C= 2 mg\u002FdL\n   * Aspartate transferase (AST) and Alanine transaminase (ALT) \\\u003C= 5.0 x upper limit of normal (ULN)\n   * Alpha gal \\\u003C 0.35 IU\u002Fml or \"negative\"\n9. Ability to provide informed consent and provision of written informed consent\n10. Stated willingness to comply with all study procedures and availability for the duration of the study\n11. Adequate cardiac function as defined as:\n\n    * No uncontrolled angina or severe ventricular arrhythmias\n    * No clinically significant pericardial disease\n    * No history of myocardial infarction (MI) in the last year before registration\n    * No Class 3 or higher New York Heart Association Congestive Heart Failure\n\nExclusion Criteria:\n\n1. Known hypersensitivity to cetuximab\n2. Treatment with investigational agent within 3 weeks prior to registration\n3. Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration\n4. Known active liver disease, human immunodeficiency virus (HIV)+ or evidence of active Hepatitis C or B virus; bleeding or condition associated with high-risk bleeding (anticoagulation is allowed)\n5. Active infection; prior antibiotic\u002Fantifungal\u002Fantiviral therapies within 2 weeks prior to registration\n6. History of a myocardial infarction within 1 year prior to registration\n7. Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n8. Autoimmune disease that has required systemic treatment with chronic steroids or immunosuppressive therapy in the 2 years prior to registration (thyroxine, insulin, or corticosteroid replacement is allowed)\n9. History or evidence of any condition that might confound the results of the trial, interfere with the subject's participation, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n10. Females must not be currently breast feeding.\n11. The treating investigator feels the patient is not able to be compliant.\n12. History of active Bacillus Tuberculosis (TB).\n13. Has received a live vaccine within 30 days of registration.\n14. Prisoners or patients who are incarcerated.\n15. Patients who are compulsorily detained for treatment of a psychiatric or physical illness.",{"count":481,"type":21},23,[121,331],"The purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood mononuclear cells (EGFR FPBMC) for patients with metastatic or unresectable pancreas cancer. Participants receive 8 twice weekly doses and then 8 more doses every 2 weeks of EGFR FPBMC by intravenous infusion.",[28,93],"2026-06-12",{"date":463,"type":34},{"date":488,"type":34},"2024-11-06",{"date":490,"type":21},"2031-06",{"name":492,"class":41},"University of Virginia",{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":22,"phases":503,"briefSummary":504,"conditions":505,"keywords":519,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":153},"100520064","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-mesothelin-targeting-logic-gated-car-t-in-participants-with-solid-tumors-that-express-msln-and-have-lost-hla-a02-expression-100520064","NCT06051695","A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","A Seamless Phase 1\u002F2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","EVEREST-2","Inclusion Criteria:\n\nKey Inclusion Criteria:\n\n1. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A\\*02 by NGS (whenever possible from the primary site), successful apheresis and PBMC processing, and with sufficient stored cells available for Tmod CAR T-cell therapy\n2. Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, PANC, OVCA, MESO, or other solid tumors with MSLN expression. Measurable disease is required with lesions of ≥1.0 cm by CT.\n3. Received previous required therapy for the appropriate solid tumor disease as described in the protocol\n4. Has adequate organ function as described in the protocol\n5. ECOG performance status of 0 to 1\n6. Life expectancy of ≥3 months\n7. Willing to comply with study schedule of assessments including long term safety follow up\n\nKey Exclusion Criteria:\n\n1. Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative\n2. Prior allogeneic stem cell transplant\n3. Prior solid organ transplant\n4. MESO with pleural involvement extending into the peritoneum\n5. Cancer therapy within 3 weeks or 3 half lives of infusion\n6. Radiotherapy within 28 days of infusion\n7. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months\n8. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated\n9. History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged steroids or other immune suppressive agents within 1 year\n10. Requires supplemental home oxygen\n11. Females of childbearing potential who are pregnant or breastfeeding\n12. Subjects, both male and female, of childbearing potential who are not willing to practice birth control from the time of consent through 6 months post infusion",{"count":502,"type":21},474,[121,331],"The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\\*02 expression.\n\nThe main questions this study aims to answer are:\n\nPhase 1: What is the recommended dose that is safe for patients\n\nPhase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells\n\nParticipants will be required to perform study procedures and assessments, and will also receive the following study treatments:\n\nEnrollment and Apheresis in BASECAMP-1 (NCT04981119)\n\nPreconditioning Lymphodepletion (PCLD) Regimen\n\nTmod CAR T cells at the assigned dose",[506,135,507,128,508,509,28,510,511,512,220,513,514,141,515,516,517,409,218,518],"Solid Tumor, Adult","NSCLC","NSCLC, Recurrent","Non-Small Cell Squamous Lung Cancer","Pancreatic Neoplasm","Colorectal Adenocarcinoma","CRC","Rectal Cancer","Cancer","Ovarian Neoplasms","Mesothelioma","Mesothelioma, Malignant","MESOM",[520,521,522,523,524,525,526,527,528,529,530,531,514,532,512,135,218,507,533,518,141,516,534],"CAR T Cell","Solid Tumors","Autologous","T Cell","Mesothelin","MSLN","HLA-A2","Solid Tumors expressing MSLN","Pancreatic","Cell Therapy","Gene Therapy","blocker","PANC","OVCA","Logic-gate","2026-06-10",{"date":485,"type":34},{"date":538,"type":34},"2024-04-03",{"date":540,"type":21},"2029-06",{"name":542,"class":152},"A2 Biotherapeutics Inc.",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":425},"100470233","marathon-of-hope-cancer-centres-network-study-for-ontario-mohccn-o-100470233","NCT05403177","Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)","MOHCCN-O","Inclusion Criteria:\n\n1. Patients with histological and\u002For cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy\n2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:\n\n   1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)\n   2. Have sufficient biospecimens (tumor and\u002For blood samples) available for more comprehensive molecular and immunophenotypic characterization\n3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.\n4. Participating patients must agree to share their anonymized clinical and genomic data\n\nExclusion Criteria:\n\nNone.",{"count":460,"type":21},"The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients",[140,135,28,344,248,409,219,337,553,218,133,554],"Lymphoma","Solid Tumor","2026-06-09",{"date":535,"type":34},{"date":558,"type":34},"2022-06-23",{"date":560,"type":21},"2030-10",{"name":562,"class":41},"University Health Network, Toronto",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":22,"phases":572,"briefSummary":573,"conditions":574,"keywords":577,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":42},"100528236","phase-1-autologous-car-t-cells-targeting-b7-h3-in-pdac-100528236","NCT06158139","Autologous CAR-T Cells Targeting B7-H3 in PDAC","A Phase I Study of Autologous CAR-T Cells Targeting the B7-H3 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Refractory Pancreatic Ductal Adenocarcinoma (PDAC)","Inclusion Criteria:\n\n1. Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for releasing personal health information explained to, understood by, and signed by the subject or legally authorized representative.\n2. Age ≥ 18 years at the time of consent.\n3. Eastern Cooperative Oncology Group of 0-1 Performance Status)\n4. Histological or cytological evidence\u002Fconfirmation of pancreatic ductal adenocarcinoma.\n5. Female subjects of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 6 months after study treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets \\\u003C 1% failure rate for protection from pregnancy in the product label.\n6. Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 3 months after the cell infusion therapy.\n\nExclusion Criteria:\n\n1. Subjects with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n2. Subject is not willing and able to comply with study procedures based on the judgment of the investigator.",{"count":571,"type":21},27,[121],"The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration.",[28,575,576],"Relapse","Resistant Cancer",[578],"cellular therapy","2026-06-05",{"date":581,"type":34},"2026-06-08",{"date":583,"type":34},"2024-07-18",{"date":585,"type":21},"2030-04",{"name":587,"class":41},"UNC Lineberger Comprehensive Cancer Center",{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":22,"phases":596,"briefSummary":597,"conditions":598,"keywords":599,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":42},"100631001","surgimedia-utilization-of-multimedia-for-enhanced-surgical-consent-100631001","NCT07494994","SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent","SURGIMEDIA","In order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\nInclusion Criteria:\n\n* Written informed consent obtained to participate in the study and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information\n* Subjects is willing and able to comply with study procedures based on the judgement of the investigator.\n* Age ≥ 18 years at the time of informed consent for study participation.\n* Scheduled to undergo a standard of care pancreaticoduodenectomy procedure.\n* English as the patient's self-reported preferred language.\n\nExclusion Criteria:\n\n* Inability to speak English.\n* Dementia altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent as determined by the study physician.\n* Currently pregnant. If a participant becomes pregnant during the study, they will be withdrawn and replaced with a new participant if resources allow.",{"count":83,"type":21},[24],"Informed consent is an ethical and legal component of the pre-procedural process. Informed consent involves the explanation of procedural steps and discussion regarding the risks, benefits, and alternatives of the proposed procedure. The current informed consent process lacks standardization, and patient experience can vary widely depending on the provider obtaining consent. This pilot study aims to ensure high quality informed consent for patients undergoing a complex oncologic operation known as a pancreaticoduodenectomy (Whipple operation), through the creation of an educational video as a method of obtaining informed consent. This study will explore whether the application of an educational video as part of the informed consent process increases patient understanding, comfort, and overall satisfaction throughout the Whipple operative course. The primary objective of this study is to determine whether implementation of a multimedia video as an enhancement to surgical informed consent improves patient satisfaction, promotes understanding, and informs operative expectations. The desired outcome is to standardize the informed consent process to eliminate variability in the quality of the consent process and to mitigate the impact of healthcare barriers such as health literacy and language proficiency in the informed consent process.",[28],[600,601,602,603,604],"informed consent","pancreaticoduodenectomy","Whipple operation","educational video","complex surgical operation","2026-06-04",{"date":581,"type":34},{"date":608,"type":21},"2026-07",{"date":610,"type":21},"2030-01",{"name":587,"class":41},{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":622,"conditions":623,"keywords":629,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":643},"100437810","solid-tumor-analysis-for-hla-loss-of-heterozygosity-loh-and-apheresis-for-car-t--cell-manufacturing-100437810","NCT04981119","Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing","An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing","BASECAMP-1","Key Eligibility Criteria (additional criteria may apply) Part 1 Key Inclusion Criteria\n\n1\\. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), or Pancreatic Cancer (PANC), that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.\n\nPart 1: Key Exclusion Criteria\n\n1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.\n2. Prior allogeneic stem cell transplant.\n3. Prior solid organ transplant.\n\nPart 2 : Key Inclusion Criteria\n\n1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PANC), Mesothelioma, or Ovarian Cancer (OVAC) that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.\n2. Participants are germline HLA-A\\*02 heterozygous confirmed by HLA typing.\n3. Primary tumor tissue showing LOH of HLA-A\\*02 by NGS testing.\n4. Eastern Cooperative Oncology Group (ECOG) 0 or 1 performance status.\n\nPart 2: Key Exclusion Criteria\n\n1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.\n2. Prior allogeneic stem cell transplant.\n3. Prior solid organ transplant.\n4. Participants who have received any cancer therapy on any investigational therapy for any indication, including but not limited to chemotherapy, small molecules, monoclonal antibodies, or radiotherapy (with bone marrow impact) within 2 weeks of planned apheresis or 3 half-lives, whichever is shorter.\n5. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment necessitating specific treatment, or any major episode of infection requiring treatment with Intravenous (IV) antimicrobials (e.g., IV antibiotics) or hospitalization (relating to completion of antibiotic course).\n6. Has known active central nervous system metastases. Subjects with previously treated brain metastases may participate upon medical monitor agreement.\n7. In the Investigator's judgement, any other condition or reason the subject would not complete the required study visits and procedures, and follow up visits, or comply with the study requirements for participation.",{"count":621,"type":21},200,"Objective:\n\nTo collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment.\n\nDesign:\n\nThis is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.",[506,135,128,93,512,507,28,516,141,515,624,517,625,514,626,627,628],"Ovarian Carcinoma","Mesothelioma; Lung","Triple Negative Breast Cancer (TNBC)","Renal Cell Carcinoma (Kidney Cancer)","Head and Neck Squamous Cell Carcinoma HNSCC",[630,631,632,633,634],"CAR T Cell Therapy","Next Generation Sequencing","Leukapheresis","Apheresis","Immunotherapy","2026-05-29",{"date":637,"type":34},"2026-06-02",{"date":639,"type":34},"2021-10-29",{"date":641,"type":21},"2029-04",{"name":542,"class":152},16,{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":22,"phases":651,"briefSummary":652,"conditions":653,"keywords":659,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":669,"locationsCount":42},"100536304","equity-gi-a-prospective-study-to-enhance-quality-inclusivity-and-trial-participation-in-black-patients-with-gastrointestinal-cancer-100536304","NCT06263088","EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.","Inclusion Criteria:\n\n1. Adult ≥ 18 years old.\n2. Newly diagnosed Black GI cancer participants irrespective of stage. Eligible tumor types include anal carcinoma, rectal cancer, colon cancer, small bowel cancer, appendix carcinoma, hepatobiliary cancer, pancreatic cancer, gastroesophageal cancer, gastrointestinal neuroendocrine tumors, and gastrointestinal stromal tumor.\n3. Patient able and willing to comply with study procedures\n4. The patient is able to understand and willing to sign and date the written informed consent form at the screening visit.\n\nExclusion Criteria:\n\n* NONE",{"count":621,"type":21},[24],"This research study is being conducted to improve the quality of care of participants who have a diagnosis of gastrointestinal cancer (anal, colon, rectal, esophageal, stomach, small bowel, appendix, pancreas, gall bladder, liver, neuroendocrine tumor of gastrointestinal origin).\n\nThis study has 3 components as follows-\n\n1. Ensuring appropriate biomarker testing and evidence-based care: Biomarkers are molecules in the tumor or blood that indicate normal or abnormal processes in participant's body and may indicate an underlying condition or disease. Various molecules, such as DNA (genes), proteins, or hormones, can serve as biomarkers since they all indicate something about participant's health. Biomarker testing can also help choose participant's treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to participant's treating physician. Participants will receive standard-of-care treatment if participant enroll in this study. Participant will not receive any experimental treatment.\n2. Assistance with clinical trial enrollment. The study team will help participants enroll in a clinical trial appropriate for participant's condition. However, enrolling in a clinical trial is totally up to the participant.\n3. Health literacy: The study team will provide information relevant to participant's diagnosis to enrich participant's understanding of participant's condition and treatment. Investigator will provide questionnaires to assess participant's understanding before and after participant's have been provided with educational\u002Finformational material appropriate for participant's diagnosis.",[654,220,513,655,656,168,657,28,169,658],"Gastrointestinal Cancer","Anal Cancer","Esophageal Cancer","Appendix Cancer","Neuroendocrine Tumors",[660,661],"Gastrointestinal cancer","African Americans","2026-05-19",{"date":664,"type":34},"2026-05-22",{"date":666,"type":34},"2024-12-01",{"date":668,"type":21},"2026-09-30",{"name":182,"class":41},{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":674,"acronym":675,"eligibilityCriteria":676,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":677,"targetDuration":4,"studyType":22,"phases":679,"briefSummary":680,"conditions":681,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":685,"startDateStruct":686,"completionDateStruct":687,"leadSponsor":689,"locationsCount":4},"100638325","statewide-unified-network-for-remote-intervention-of-strength-and-exercise-100638325","NCT07596732","Statewide Unified Network for Remote Intervention of Strength and Exercise","SUNRISE","Inclusion Criteria:\n\n* Gastrointestinal cancer (esophageal, gastric, pancreatic, colon, and rectal) treated with chemotherapy (and other treatments, as clinically indicated) before surgery OR Lung cancer (non-small cell and small-cell) treated with chemotherapy (and other treatments, as clinically indicated) for advanced- or extensive-stage disease.\n* Completion of the modified version of the Physical Activity Readiness Questionnaire.\n\nExclusion Criteria:\n\n* Actively treated for another non-gastrointestinal or non-lung malignancy (surveillance with observation is allowed).\n* Engage in more than 150 minutes per week of aerobic physical activity and two or more sessions of muscle strengthening activity per week over the last three months (self-report).\n* Unable to walk for 6 minutes or two city blocks independently (self-report).\n* Enrollment in another study that intervenes upon physical activity, diet, or body composition as a primary objective (self-report).\n* Unable to read and speak English.\n* No access to a reliable internet connection.\n* Currently an AdventHealth employee.",{"count":678,"type":21},120,[24],"This study will evaluate whether a remotely delivered exercise program can improve chemotherapy tolerability in patients with gastrointestinal or lung cancer receiving chemotherapy.\n\nIn this decentralized, digital randomized clinical trial, up to 120 adults with gastrointestinal or lung cancer will be randomized to either a home-based aerobic and resistance exercise program or home-based progressive stretching program. All study activities will be conducted remotely using digital technologies and home-based assessments. Participants in both groups will receive Bluetooth-enabled wearable devices for monitoring physical activity, body weight, blood pressure, and other health measures.\n\nThe primary objective is to determine whether exercise improves chemotherapy relative dose intensity compared with stretching. The intervention will continue throughout chemotherapy treatment or for up to 32 weeks.",[682,683,28,220,513,218],"Gastric Cancer (Diagnosis)","Esophagus Cancer","2026-05-13",{"date":662,"type":34},{"date":446,"type":21},{"date":688,"type":21},"2027-12-31",{"name":690,"class":41},"AdventHealth Translational Research Institute",{"id":692,"slug":693,"hasResults":12,"nctId":694,"briefTitle":695,"officialTitle":696,"acronym":697,"eligibilityCriteria":698,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":699,"targetDuration":4,"studyType":22,"phases":701,"briefSummary":702,"conditions":703,"keywords":704,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":708,"lastUpdatePostDateStruct":709,"startDateStruct":711,"completionDateStruct":713,"leadSponsor":715,"locationsCount":716},"100535493","promoting-ct-engagement-for-pancreatic-cancer-with-app-100535493","NCT06252545","Promoting CT Engagement for Pancreatic Cancer With App","PROmoting CLinicAl TrIal EngageMent for Pancreatic Cancer App Study (PROCLAIM Study","PROCLAIM","Inclusion Criteria\n\nParticipants must meet the following inclusion criteria in order to participate in communication \\& education interview component of the study:\n\n1. Informed consent obtained to participate in the study\n2. 18 years or older\n3. English speaking\n4. Able and willing to participate in a 1-hour interview\n5. History of pancreatic cancer diagnosis\n6. Identify as Black\n\nExclusion Criteria:\n\nAll participants meeting any of the following exclusion criteria will be excluded from the study:\n\n1. Inability to read and speak English\n2. Dementia altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent as determined by the study physician.",{"count":700,"type":21},26,[24],"To develop a culturally tailored informational mobile application and test whether it will increase participation among Black pancreatic cancer subjects in clinical trial discussions with their care team.\n\nThis project aims to identify and address barriers to enrollment of Black subjects in pancreatic cancer clinical trials using a culturally informed mobile health application to promote participation.\n\nThe clinical trial education and communication needs of Black people with pancreatic cancer will be determined. A new mHealth application for clinical trial education and communication tailored to subject needs will be developed. It was hypothesized that a culturally tailored informational mobile application will increase the participation of Black subjects in clinical trial discussions with their care team among the target population.\n\nThis study focuses on Black pancreatic cancer subjects, who experience higher mortality rates and lower clinical trial participation than White subjects. Research shows that the disparity between clinical trial participation is in part due to inequitable recruitment practices. This study will use mobile application technology (mHealth app) as an educational, communication, audit, and feedback tool to promote patient-initiated clinical trial discussions among Black people with pancreatic cancer and their cancer care team.",[28],[705,706,707],"ethnicity","black","application","2026-05-11",{"date":710,"type":34},"2026-05-14",{"date":712,"type":34},"2024-02-02",{"date":714,"type":21},"2027-02-01",{"name":587,"class":41},2]